Error in Author Surname

No authors listed

Published Erratum

No authors listed. JAMA Oncol. 2022.

. 2022 May 1;8(5):784.

doi: 10.1001/jamaoncol.2022.0909.

No abstract available

Erratum for

Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial.
Pivot X, Georgievich MA, Shamrai V, Dzagnidze G, Soo Hoo HF, Kaewkangsadan V, Petrelli F, Villanueva C, Nikolaevich LO, Hii J, Kim J, Pradhan S, Jaison L, Feyaerts P, Kaufman L, Derde MP, Bonamy GMC, Deforce F, Cox DG. Pivot X, et al. JAMA Oncol. 2022 May 1;8(5):698-705. doi: 10.1001/jamaoncol.2021.8171. JAMA Oncol. 2022. PMID: 35238873 Free PMC article. Clinical Trial.

1. Pivot X, Georgievich MA, Shamrai V, et al. . Efficacy of HD201 vs referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting: a multicenter phase 3 randomized clinical trial. JAMA Oncol. Published online March 3, 2022. doi:10.1001/jamadermatol.2021.8171 - DOI - PMC - PubMed